IDEAYA reports Q3 net income $119.2M, cash $1.14B; darovasertib partnership with Servier closed

IDEAYA Biosciences, Inc.

2025-Q3 EPS reported -$0.34 revenue$207,834,000

Net income of $119.2M vs Q2 net loss of $77.5M; collaboration revenue $207.8M from Servier license.
Cash, equivalents, marketable securities $1.14B (up from $991.9M Q2); funded into 2030.
Darovasertib Phase 2/3 OptimUM-02 median PFS data due by year-end 2025 to Q1 2026; trial nearing full enrollment.
IDE849 DLL3 ADC in SCLC: 80.0% ORR in 2L patients at 2.4 mg/kg; median PFS 6.7 months across all lines.
IND clearance for IDE892 (PRMT5) in Q3; IND filed for IDE034 (bispecific ADC); IDE574 IND on track for year-end.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.